Persistence of antibiotic resistance in bacterial populations

FEMS Microbiology Reviews

Volumn 35, Issue 5, 2011, Pages 901-911

  Andersson, Dan I ^a   Hughes, Diarmaid ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bacterial fitness; Compensatory evolution; Minimal inhibitory concentration (MIC); Reversibility; Selective window; Susceptibility

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; COTRIMOXAZOLE; ERYTHROMYCIN; MECILLINAM; NITROFURANTOIN; SULFONAMIDE;

ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIUM; CHROMOSOME; DRUG USE; HUMAN; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PLASMID; REVIEW; TRANSPOSON;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; GENE TRANSFER, HORIZONTAL; HUMANS; MODELS, THEORETICAL; SELECTION, GENETIC;

BACTERIA (MICROORGANISMS);

EID: 79960941796     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2011.00289.x     Document Type: Review

References (101)

1. Abdulkarim F & Hughes D (1996) Homologous recombination between the tuf genes of Salmonella typhimurium. J Mol Biol 260: 506-522.
2. Aldeyab MA, Monnet DL, Lopez-Lozano JM, Hughes CM, Scott MG, Kearney MP, Magee FA & McElnay JC (2008) Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemoth 62: 593-600.
3. Andersson DI (2003) Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 6: 452-456.
4. Andersson DI & Hughes D (2009) Gene amplification and adaptive evolution in bacteria. Annu Rev Genet 43: 167-195.
5. Andersson DI & Hughes D (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8: 260-271.
6. Andersson DI & Levin BR (1999) The biological cost of antibiotic resistance. Curr Opin Microbiol 2: 489-493.
7. Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S & Kristinsson KG (2002) Clonal spread of resistant pneumococci despite diminished antimicrobial use. Microb Drug Resist 8: 187-192.
8. Arthur M, Molinas C & Courvalin P (1992) The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 174: 2582-2591.
9. Arthur M, Reynolds P & Courvalin P (1996) Glycopeptide resistance in enterococci. Trends Microbiol 4: 401-407.
10. Austin DJ & Anderson RM (1999) Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos T Roy Soc B 354: 721-738.
11. Austin DJ, Kristinsson KG & Anderson RM (1999) The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. P Natl Acad Sci USA 96: 1152-1156.
12. Bahl MI, Hansen LH & Sorensen SJ (2009) Persistence mechanisms of conjugative plasmids. Methods Mol Biol 532: 73-102.
13. Baquero F, Negri MC, Morosini MI & Blazquez J (1997) The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Ciba Found Symp 207: 93-105; discussion 105-111.
14. Bean DC, Livermore DM, Papa I & Hall LM (2005) Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemoth 56: 962-964.
15. Bergman M, Huikko S, Pihlajamaki M, Laippala P, Palva E, Huovinen P & Seppala H (2004) Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis 38: 1251-1256.
16. Bergman M, Nyberg ST, Huovinen P, Paakkari P & Hakanen AJ (2009) Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Ch 53: 912-917.
17. Bjorkman J, Hughes D & Andersson DI (1998) Virulence of antibiotic-resistant Salmonella typhimurium. P Natl Acad Sci USA 95: 3949-3953.
18. Bjorkman J, Samuelsson P, Andersson DI & Hughes D (1999) Novel ribosomal mutations affecting translational accuracy, antibiotic resistance and virulence of Salmonella typhimurium. Mol Microbiol 31: 53-58.
19. Bjorkman J, Nagaev I, Berg OG, Hughes D & Andersson DI (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287: 1479-1482.
20. Bonten MJ, Austin DJ & Lipsitch M (2001) Understanding the spread of antibiotic resistant pathogens in hospitals: mathematical models as tools for control. Clin Infect Dis 33: 1739-1746.
21. Bottger EC, Springer B, Pletschette M & Sander P (1998) Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 4: 1343-1344.
22. Bouma JE & Lenski RE (1988) Evolution of a bacteria/plasmid association. Nature 335: 351-352.
23. Bugg TD, Wright GD, Dutka-Malen S, Arthur M, Courvalin P & Walsh CT (1991) Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30: 10408-10415.
24. Cabello FC (2006) Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ Microbiol 8: 1137-1144.
25. Cohen T, Sommers B & Murray M (2003) The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 3: 13-21.
26. Cosgrove SE (2006) The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 (suppl 2): S82-S89.
27. Criswell D, Tobiason VL, Lodmell JS & Samuels DS (2006) Mutations conferring aminoglycoside and spectinomycin resistance in Borrelia burgdorferi. Antimicrob Agents Ch 50: 445-452.
28. Dahlberg C & Chao L (2003) Amelioration of the cost of conjugative plasmid carriage in Eschericha coli K12. Genetics 165: 1641-1649.
29. De Gelder L, Ponciano JM, Abdo Z, Joyce P, Forney LJ & Top EM (2004) Combining mathematical models and statistical methods to understand and predict the dynamics of antibiotic-sensitive mutants in a population of resistant bacteria during experimental evolution. Genetics 168: 1131-1144.
30. Depuydt PO, Vandijck DM, Bekaert MA, Decruyenaere JM, Blot SI, Vogelaers DP & Benoit DD (2008) Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care 12: R142.
31. Dionisio F, Conceicao IC, Marques AC, Fernandes L & Gordo I (2005) The evolution of a conjugative plasmid and its ability to increase bacterial fitness. Biol Lett 1: 250-252.
32. Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemoth 52: 11-17.
33. Drlica K & Zhao X (2007) Mutant selection window hypothesis updated. Clin Infect Dis 44: 681-688.
34. Enne VI, Livermore DM, Stephens P & Hall LM (2001) Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357: 1325-1328.
35. Enne VI, Bennett PM, Livermore DM & Hall LM (2004) Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. J Antimicrob Chemoth 53: 958-963.
36. Enne VI, Delsol AA, Davis GR, Hayward SL, Roe JM & Bennett PM (2005) Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. J Antimicrob Chemoth 56: 544-551.
37. Foucault ML, Courvalin P & Grillot-Courvalin C (2009) Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Ch 53: 2354-2359.
38. Guay DR (2008) Contemporary management of uncomplicated urinary tract infections. Drugs 68: 1169-1205.
39. Handel A, Regoes RR & Antia R (2006) The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol 2: e137.
40. Heisig P (1996) Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Ch 40: 879-885.
41. Helms M, Vastrup P, Gerner-Smidt P & Molbak K (2002) Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg Infect Dis 8: 490-495.
42. Hossain A, Reisbig MD & Hanson ND (2004) Plasmid-encoded functions compensate for the biological cost of AmpC overexpression in a clinical isolate of Salmonella typhimurium. J Antimicrob Chemoth 53: 964-970.
43. Hughes D (1990) Both genes for EF-Tu in Salmonella typhimurium are individually dispensable for growth. J Mol Biol 215: 41-51.
44. Hughes D (2000) Co-evolution of the tuf genes links gene conversion with the generation of chromosomal inversions. J Mol Biol 297: 355-364.
45. Jacoby G, Cattoir V, Hooper D, Martinez-Martinez L, Nordmann P, Pascual A, Poirel L & Wang M (2008) qnr Gene nomenclature. Antimicrob Agents Ch 52: 2297-2299.
46. Jacoby GA (2009) AmpC beta-lactamases. Clin Microbiol Rev 22: 161-182.
47. Johanson U, Aevarsson A, Liljas A & Hughes D (1996) The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. J Mol Biol 258: 420-432.
48. Johnsen PJ, Simonsen GS, Olsvik O, Midtvedt T & Sundsfjord A (2002) Stability, persistence, and evolution of plasmid-encoded VanA glycopeptide resistance in enterococci in the absence of antibiotic selection in vitro and in gnotobiotic mice. Microb Drug Resist 8: 161-170.
49. Kataja J, Huovinen P, Skurnik M & Seppala H (1999) Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance. Antimicrob Agents Ch 43: 48-52.
50. Komp Lindgren P, Karlsson Å & Hughes D (2003) Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Ch 47: 3222-3232.
51. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N & Hughes D (2005) Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Ch 49: 2343-2351.
52. Kristinsson KG (1997) Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist 3: 117-123.
53. Kummerer K (2009) Antibiotics in the aquatic environment - a review-part I. Chemosphere 75: 417-434.
54. Kurland CG, Hughes D & Ehrenberg M (1996) Limitations of translational accuracy. Escherichia coli and Salmonella: cellular and molecular biology, Vol. 1 (Neidhardt F.C., et al, pp. 979-1004. ASM Press, Washington, DC.
55. Lenski RE & Bouma JE (1987) Effects of segregation and selection on instability of plasmid pACYC184 in Escherichia coli B. J Bacteriol 169: 5314-5316.
56. Levin BR (2001) Minimizing potential resistance: a population dynamics view. Clin Infect Dis 33 (suppl 3): S161-S169.
57. Levin BR (2002) Models for the spread of resistant pathogens. Neth J Med 60 (suppl): 58-64; discussion 64-66.
58. Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, Simonsen L, Walker NM & Stewart FM (1997) The population genetics of antibiotic resistance. Clin Infect Dis 24 (suppl 1): S9-S16.
59. Levin BR, Perrot V & Walker N (2000) Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154: 985-997.
60. Lew W, Pai M, Oxlade O, Martin D & Menzies D (2008) Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149: 123-134.
61. Li D, Yang M, Hu J, Ren L, Zhang Y & Li K (2008) Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. Environ Toxicol Chem 27: 80-86.
62. Lind PA, Tobin C, Berg OG, Kurland CG & Andersson DI (2010) Compensatory gene amplification restores fitness after inter-species gene replacements. Mol Microbiol 75: 1078-1089.
63. Lipsitch M, Bergstrom CT & Levin BR (2000) The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. P Natl Acad Sci USA 97: 1938-1943.
64. Liu A, Fong A, Becket E et al. (2011) Selective advantage of resistant strains at trace levels of antibiotics: a simple and ultrasensitive color test for detection of antibiotics and genotoxic agents. Antimicrob Agents Ch 55: 1204-1210.
65. Lundquist PD & Levin BR (1986) Transitory derepression and the maintenance of conjugative plasmids. Genetics 113: 483-497.
66. Luo N, Pereira S, Sahin O, Lin J, Huang S, Michel L & Zhang Q (2005) Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. P Natl Acad Sci USA 102: 541-546.
67. Mahamat A, MacKenzie FM, Brooker K, Monnet DL, Daures JP & Gould IM (2007) Impact of infection control interventions and antibiotic use on hospital MRSA: a multivariate interrupted time-series analysis. Int J Antimicrob Ag 30: 169-176.
68. Maisnier-Patin S, Berg OG, Liljas L & Andersson DI (2002) Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol 46: 355-366.
69. Marcusson LL, Frimodt-Moller N & Hughes D (2009) Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5: e1000541.
70. Martinez-Martinez L, Pascual A & Jacoby GA (1998) Quinolone resistance from a transferable plasmid. Lancet 351: 797-799.
71. McGowan JE Jr (1986) Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect Control 7: 573-576.
72. Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, Moellering RC Jr & Jenkins SG (2004a) Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemoth 54: 818-820.
73. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC Jr & Gold HS (2004b) Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 190: 311-317.
74. Morosini MI, Ayala JA, Baquero F, Martinez JL & Blazquez J (2000) Biological cost of AmpC production for Salmonella enterica serotype Typhimurium. Antimicrob Agents Ch 44: 3137-3143.
75. Nagaev I, Bjorkman J, Andersson DI & Hughes D (2001) Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 40: 433-439.
76. Negri MC, Lipsitch M, Blazquez J, Levin BR & Baquero F (2000) Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob Agents Ch 44: 2485-2491.
77. Nilsson AI, Zorzet A, Kanth A, Dahlstrom S, Berg OG & Andersson DI (2006) Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. P Natl Acad Sci USA 103: 6976-6981.
78. Olofsson SK, Marcusson LL, Stromback A, Hughes D & Cars O (2007) Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemoth 60: 795-801.
79. Örlén H & Hughes D (2006) Weak mutators can drive the evolution of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Ch 50: 3454-3456.
80. Pallecchi L, Bartoloni A, Paradisi F & Rossolini GM (2008) Antibiotic resistance in the absence of antimicrobial use: mechanisms and implications. Expert Rev Anti Infect Ther 6: 725-732.
81. Paulander W, Maisnier-Patin S & Andersson DI (2009) The fitness cost of streptomycin resistance depends on rpsL mutation, carbon source and RpoS ({sigma}S). Genetics 183: 539-546.
82. Perichon B & Courvalin P (2009) VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Ch 53: 4580-4587.
83. Perichon B, Courvalin P & Galimand M (2007) Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Ch 51: 2464-2469.
84. Ramadhan AA & Hegedus E (2005) Survivability of vancomycin resistant enterococci and fitness cost of vancomycin resistance acquisition. J Clin Pathol 58: 744-746.
85. Roberts RR, Hota B & Ahmad I (2009) Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 49: 1175-1184.
86. Robicsek A, Jacoby GA & Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 6: 629-640.
87. Rozen DE, McGee L, Levin BR & Klugman KP (2007) Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Ch 51: 412-416.
88. Sandegren L & Andersson DI (2009) Bacterial gene amplification: implications for the evolution of antibiotic resistance. Nat Rev Microbiol 7: 578-588.
89. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M & Bottger EC (2002) Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Ch 46: 1204-1211.
90. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K & Huovinen P (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. New Engl J Med 337: 441-446.
91. Sipahi OR (2008) Economics of antibiotic resistance. Expert Rev Anti Infect Ther 6: 523-539.
92. Smith MA & Bidochka MJ (1998) Bacterial fitness and plasmid loss: the importance of culture conditions and plasmid size. Can J Microbiol 44: 351-355.
93. Sommer MO, Dantas G & Church GM (2009) Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325: 1128-1131.
94. Sundqvist M, Geli P, Andersson DI, Sjolund-Karlsson M, Runehagen A, Cars H, Abelson-Storby K, Cars O & Kahlmeter G (2009) Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemoth 65: 350-360.
95. Thiele-Bruhn S (2003) Pharmaceutical antibiotic compounds in soils - a review. J Plant Nutr Soil Sc 166: 145-167.
96. Tubulekas I & Hughes D (1993) Suppression of rpsL phenotypes by tuf mutations reveals a unique relationship between translation elongation and growth rate. Mol Microbiol 7: 275-284.
97. Willems RJ, Top J, van Santen M, Robinson DA, Coque TM, Baquero F, Grundmann H & Bonten MJ (2005) Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 11: 821-828.
98. Wise R (2002) Antimicrobial resistance: priorities for action. J Antimicrob Chemoth 49: 585-586.
99. Wolter N, Smith AM, Farrell DJ & Klugman KP (2006) Heterogeneous macrolide resistance and gene conversion in the pneumococcus. Antimicrob Agents Ch 50: 359-361.
100. Woodford N & Livermore DM (2009) Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 59 (suppl 1): S4-S16.
101. Yates CM, Shaw DJ, Roe AJ, Woolhouse ME & Amyes SG (2006) Enhancement of bacterial competitive fitness by apramycin resistance plasmids from non-pathogenic Escherichia coli. Biol Lett 2: 463-465.